Pharmacyclics (PCYC) Scheduled to Post Earnings on Friday
Pharmacyclics (NASDAQ:PCYC) is scheduled to be posting its Q114 quarterly earnings results on Friday, May 2nd. Analysts expect Pharmacyclics to post earnings of $0.17 per share and revenue of $105.38 million for the quarter.
Pharmacyclics (NASDAQ:PCYC) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.28. The company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $85.69 million.
Shares of Pharmacyclics (NASDAQ:PCYC) opened at 94.58 on Thursday. Pharmacyclics has a 52-week low of $74.36 and a 52-week high of $154.89. The stock has a 50-day moving average of $103.5 and a 200-day moving average of $120.5. The company has a market cap of $7.073 billion and a price-to-earnings ratio of 111.21.
A number of analysts have recently weighed in on PCYC shares. Analysts at Zacks reiterated a “neutral” rating on shares of Pharmacyclics in a research note on Monday. They now have a $93.00 price target on the stock. On a related note, analysts at Ned Davis Research upgraded shares of Pharmacyclics from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Finally, analysts at Morgan Stanley initiated coverage on shares of Pharmacyclics in a research note on Wednesday, March 26th. They set an “equal weight” rating and a $120.00 price target on the stock. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $152.13.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.